drugset / Trial / NCT00720928
Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease
Phase 4
Unknown
15 enrolled
Asan Medical Center
Kyunghee University Medical Center · collabSamsung Medical Center · collabSeoul National University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Objectives: To describe the safety and efficacy of intravitreal flucinolone acetonide implants in the management of patients having refractory ocular Behcet's disease Hypothesis: A descriptive observational study Study design: A 1-year, multi-center (including four Korean medical centers) observational study
Timeline
- Start
- 2008-07
- Primary completion
- 2009-12
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fluocinolone acetonide | Small molecule | 0.59 mg | Intravitreal |